Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 12/20 | 0.68 |
| ▸ | CTSL | P07711 | 2/20 | 0.59 |
| ▸ | CTSS | P25774 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4935969 | 0.92 | TGM2 (0.77) | TGM2CTSLCTSSCYP1A2CTSB | |
| SCHEMBL4598859 | 0.91 | TGM2 (0.66) | TGM2CTSLCTSSCYP1A2CTSB | |
| SCHEMBL9825862 | 0.90 | CTSL (0.58) | TGM2CTSLCTSSCYP1A2CTSB | |
| SCHEMBL1091900 | 0.89 | TGM2 (0.72) | TGM2CYP1A2ATM | |
| SCHEMBL1103747 | 0.89 | TGM2 (0.72) | TGM2CYP1A2ATM | |
| SCHEMBL1091898 | 0.89 | TGM2 (0.72) | TGM2CYP1A2ATM | |
| SCHEMBL9825197 | 0.89 | CTSL (0.57) | TGM2CTSLCTSSCYP1A2CTSB | |
| SCHEMBL9825235 | 0.87 | TGM2 (0.71) | TGM2CTSLCTSSCYP1A2 | |
| SCHEMBL9826129 | 0.86 | CTSL (0.54) | TGM2CTSLCTSSCYP1A2CTSB | |
| SCHEMBL9825533 | 0.85 | TGM2 (0.69) | TGM2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0237082-B1 | 3,5-DISUBSTITUTED 4,5-DIHYDROISOXAZOLES AS TRANSGLUTAMINASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1991-05-29 | — | — | EP | claimed |
| EP-0237082-A2 | 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors | SYNTEX (U.S.A.) INC. (US) | 1987-09-16 | — | — | EP | claimed |
| US-20080299170-A1 | Medical Devices and Coatings Therefor | ASTON UNIVERSITY (GB) | 2008-12-04 | — | — | US | disclosed |
| EP-1907027-A2 | MEDICAL DEVICES AND COATINGS THEREFOR | Aston University (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007010201-A2 | MEDICAL DEVICES AND COATINGS THEREFOR | ASTON UNIVERSITY (GB) | 2007-01-25 | — | — | WO | disclosed |
| EP-0237082-B1 | 3,5-DISUBSTITUTED 4,5-DIHYDROISOXAZOLES AS TRANSGLUTAMINASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1991-05-29 | — | — | EP | disclosed |
| US-4929630-A | SKIN DISORDERS, ACNE, 4,5-DIHYDROISOOXAZOLE PEPTIDES | SYNTEX (U.S.A.) INC. (US) | 1990-05-29 | — | — | US | disclosed |
| US-4912120-A | Containing amine and amide substitution | SYNTEX (U.S.A.) INC. (US) | 1990-03-27 | — | — | US | disclosed |
| EP-0237082-A2 | 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors | SYNTEX (U.S.A.) INC. (US) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299170-A1 | Medical Devices and Coatings Therefor | F8, HABP2, TFPI | TGM2 16/4885CTSL 104/4885CTSS 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.